Baseline blood eosinophil count as a predictor of treatment response to the licensed dose of mepolizumab in severe eosinophilic asthma.
- DOI
- 10.1016/j.rmed.2019.105806
- Published
- 2019 Nov
- Container
- Respiratory medicine
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.rmed.2019.105806,
title = {Baseline blood eosinophil count as a predictor of treatment response to the licensed dose of mepolizumab in severe eosinophilic asthma.},
author = {Albers FC and Licskai C and Chanez P and Bratton DJ and Bradford ES and Yancey SW and Kwon N and Quirce S},
year = {2019},
journal = {Respiratory medicine},
doi = {10.1016/j.rmed.2019.105806},
url = {https://doi.org/10.1016/j.rmed.2019.105806}
}RIS
TY - JOUR TI - Baseline blood eosinophil count as a predictor of treatment response to the licensed dose of mepolizumab in severe eosinophilic asthma. AU - Albers FC AU - Licskai C AU - Chanez P AU - Bratton DJ AU - Bradford ES AU - Yancey SW AU - Kwon N AU - Quirce S PY - 2019 JO - Respiratory medicine DO - 10.1016/j.rmed.2019.105806 UR - https://doi.org/10.1016/j.rmed.2019.105806 ER -
APA
FC, A., C, L., P, C., DJ, B., ES, B., SW, Y., N, K., & S, Q. (2019). Baseline blood eosinophil count as a predictor of treatment response to the licensed dose of mepolizumab in severe eosinophilic asthma.. Respiratory medicine. https://doi.org/10.1016/j.rmed.2019.105806
Source records
- pubmed · retrieved 2026-09-27T00:21:24.858Z